476 related articles for article (PubMed ID: 17111439)
1. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
2. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
[TBL] [Abstract][Full Text] [Related]
3. Functional genomics dissects pathomechanisms in tauopathies: mitosis failure and unfolded protein response.
Götz J; David D; Hoerndli F; Ke YD; Schonrock N; Wiesner A; Fath T; Bokhari L; Lim YA; Deters N; Ittner LM
Neurodegener Dis; 2008; 5(3-4):179-81. PubMed ID: 18322384
[TBL] [Abstract][Full Text] [Related]
4. Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry.
Hoerndli FJ; Pelech S; Papassotiropoulos A; Götz J
Eur J Neurosci; 2007 Jul; 26(1):60-72. PubMed ID: 17587323
[TBL] [Abstract][Full Text] [Related]
5. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils.
Götz J; Chen F; van Dorpe J; Nitsch RM
Science; 2001 Aug; 293(5534):1491-5. PubMed ID: 11520988
[TBL] [Abstract][Full Text] [Related]
6. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
7. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.
Lewis J; Dickson DW; Lin WL; Chisholm L; Corral A; Jones G; Yen SH; Sahara N; Skipper L; Yager D; Eckman C; Hardy J; Hutton M; McGowan E
Science; 2001 Aug; 293(5534):1487-91. PubMed ID: 11520987
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
10. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
Ribé EM; Pérez M; Puig B; Gich I; Lim F; Cuadrado M; Sesma T; Catena S; Sánchez B; Nieto M; Gómez-Ramos P; Morán MA; Cabodevilla F; Samaranch L; Ortiz L; Pérez A; Ferrer I; Avila J; Gómez-Isla T
Neurobiol Dis; 2005 Dec; 20(3):814-22. PubMed ID: 16125396
[TBL] [Abstract][Full Text] [Related]
11. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.
Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L
Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645
[TBL] [Abstract][Full Text] [Related]
13. Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.
Kawasumi M; Chiba T; Yamada M; Miyamae-Kaneko M; Matsuoka M; Nakahara J; Tomita T; Iwatsubo T; Kato S; Aiso S; Nishimoto I; Kouyama K
Eur J Neurosci; 2004 May; 19(10):2826-38. PubMed ID: 15147316
[TBL] [Abstract][Full Text] [Related]
14. Different tau epitopes define Abeta42-mediated tau insolubility.
Pennanen L; Götz J
Biochem Biophys Res Commun; 2005 Dec; 337(4):1097-101. PubMed ID: 16226718
[TBL] [Abstract][Full Text] [Related]
15. Dissecting toxicity of tau and beta-amyloid.
Götz J; Lim YA; Ke YD; Eckert A; Ittner LM
Neurodegener Dis; 2010; 7(1-3):10-2. PubMed ID: 20160450
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
17. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
18. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
19. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
Kuzuhara S
Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
[TBL] [Abstract][Full Text] [Related]
20. [Biological characteristics of amyloid precursor protein and Alzheimer's disease].
Fukatsu R; Tsuzuki K; Takamaru Y; Hayashi Y; Sasaki N; Yoshida T; Midorikawa Y; Fujii N; Takahata N
Rinsho Byori; 1996 Mar; 44(3):213-24. PubMed ID: 8857163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
